Christopher S. Jones

Proteolytic Activity of Human Osteoclast Cathepsin K

Mary J. Bossard, Thaddeus A. Tomaszek, Scott K. Thompson et al. · Journal of Biological Chemistry · 1996 · 488 citations · Full text

Discovery of PF-04449913, a Potent and Orally Bioavailable Inhibitor of Smoothened

Michael J. Munchhof, Qifang Li, Andrei Shavnya et al. · ACS Medicinal Chemistry Letters · 2011 · 158 citations · Full text

Pharmaceutical Science, Chemoprevention Strategy, Smoothened Inhibitor +20

Autocatalytic Activation of Human Cathepsin K

Michael S. McQueney, Bernard Y. Amegadzie, Karla D'Alessio et al. · Journal of Biological Chemistry · 1997 · 155 citations · Full text

Discovery of (<i>S</i>)-6-(3-Cyclopentyl-2-(4-(trifluoromethyl)-1<i>H</i>-imidazol-1-yl)propanamido)nicotinic Acid as a Hepatoselective Glucokinase Activator Clinical Candidate for Treating Type 2 Diabetes Mellitus

Jeffrey A. Pfefferkorn, Angel Guzmán-Pérez, John Litchfield et al. · Journal of Medicinal Chemistry · 2011 · 114 citations · Full text

Designing glucokinase activators with reduced hypoglycemia risk: discovery of N,N-dimethyl-5-(2-methyl-6-((5-methylpyrazin-2-yl)-carbamoyl)benzofuran-4-yloxy)pyrimidine-2-carboxamide as a clinical candidate for the treatment of type 2 diabetes mellitus

Jeffrey A. Pfefferkorn, Angel Guzmán-Pérez, Peter J. Oates et al. · MedChemComm · 2011 · 68 citations